These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

541 related items for PubMed ID: 32859552

  • 1. Evaluating the antibacterial activity of ceftaroline against clinical isolates of methicillin-susceptible and- resistant Staphylococcus aureus in Kuwait hospitals.
    Alfouzan W, Boswihi SS, Dhar R, Udo E.
    J Infect Public Health; 2020 Oct; 13(10):1589-1591. PubMed ID: 32859552
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers.
    Sader HS, Farrell DJ, Flamm RK, Jones RN.
    Surg Infect (Larchmt); 2016 Aug; 17(4):443-7. PubMed ID: 26990170
    [Abstract] [Full Text] [Related]

  • 3. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.
    Sader HS, Flamm RK, Farrell DJ, Jones RN.
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S181-6. PubMed ID: 22903950
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vitro activity of ceftaroline: A novel antibiotic against methicillin-resistant Staphylococcus aureus.
    Gaikwad V, Gohel T, Panickar S, Chincholkar V, Mangalkar S.
    Indian J Pathol Microbiol; 2016 Sep; 59(4):496-498. PubMed ID: 27721280
    [Abstract] [Full Text] [Related]

  • 7. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP, Noel AR, Tomaselli S, Bowker KE.
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2451-6. PubMed ID: 23459495
    [Abstract] [Full Text] [Related]

  • 8. [In vitro activity of ceftaroline against Spanish isolates of Staphylococcus aureus: a multicenter study].
    Tenorio-Abreu A, Gil Tomás J, Bratos Pérez MÁ, de la Iglesia Salgado A, Borrás Máñez M, Ortiz de Lejarazu Leonardo R, Ávila Alonso A, Colomina Rodríguez J, Pérez Cáceres JA, Saavedra Martín JM, Márquez Sanabria A, Domínguez Castaño A, de la Iglesia Salgado M.
    Enferm Infecc Microbiol Clin; 2015 Feb; 33(2):101-4. PubMed ID: 25091384
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections.
    Hodille E, Delouere L, Bouveyron C, Meugnier H, Bes M, Tristan A, Laurent F, Vandenesch F, Lina G, Dumitrescu O.
    Med Mal Infect; 2017 Mar; 47(2):152-157. PubMed ID: 27856079
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
    Pfaller MA, Mendes RE, Castanheira M, Flamm RK, Jones RN, Sader HS.
    Pediatr Infect Dis J; 2017 May; 36(5):486-491. PubMed ID: 28403050
    [Abstract] [Full Text] [Related]

  • 14. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
    Sader HS, Mendes RE, Farrell DJ, Flamm RK, Jones RN.
    Pediatr Infect Dis J; 2014 Aug; 33(8):837-42. PubMed ID: 25222304
    [Abstract] [Full Text] [Related]

  • 15. Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013-2014 at the Geneva University Hospitals.
    Andrey DO, François P, Manzano C, Bonetti EJ, Harbarth S, Schrenzel J, Kelley WL, Renzoni A.
    Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):343-350. PubMed ID: 27744604
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [In vitro activity of ceftaroline to MRSA isolates: a multicenter study].
    Mengeloğlu FZ, Taş T, Koçoğlu E, Copur Çiçek A, Yanık K, Güneş H, Ciftci IH, Durmaz S, Bucak O, Güçkan R, Terzi HA, Yavuz MZ.
    Mikrobiyol Bul; 2013 Oct; 47(4):677-83. PubMed ID: 24237436
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.
    Karlowsky JA, Adam HJ, Decorby MR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG.
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2837-46. PubMed ID: 21402844
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of meropenem/piperacillin/tazobactam triple combination therapy against clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus pseudintermedius and vancomycin-resistant Enterococcus spp.
    Yoneda A, Thänert R, Burnham CD, Dantas G.
    Int J Antimicrob Agents; 2020 Feb; 55(2):105864. PubMed ID: 31870598
    [Abstract] [Full Text] [Related]

  • 20. In vitro activity of ceftaroline and ceftobiprole against methicillin-resistant Staphylococcus aureus with decreased susceptibility to vancomycin isolated in paediatric patients.
    Carnesecchi G, Lobello R, Liggieri L, Palmero C, Pescetto L, Morelli P, Castagnola E, Bandettini R.
    J Chemother; 2018 Feb; 30(6-8):338-341. PubMed ID: 30375268
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.